Sildenafil and Stroke Recovery

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Stroke

In brief

This is a small, pilot randomized clinical trial of administering sildenafil citrate to individuals within 10 days of ischemic stroke who have motor impairment and who are undergoing inpatient rehabilitation compared to placebo. The primary outcome is motor recovery at one and three months.

Key facts

Study ID

NCT02628847

Run by

University of Utah

People needed

11

Starts

2012-03-01

Expected to finish

2016-10-01

Last updated by the study team

2017-01-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• between 4 and 9 days post-ischemic stroke;
• admitted to inpatient rehabilitation;
• cognitively able to provide consent or assent;
• were living independently in the community prior to their stroke.

You may not qualify if…

• hemorrhagic stroke or subarachnoid hemorrhage;
• other neurological or psychiatric conditions deemed by the investigator to impair participation;
• no previous stroke on same side of brain unless that stroke was cerebellar
• moribound or not expected to live 6 months;
• contraindications to taking sildenafil in pill or syrup form;
• other medical conditions that would limit ability to participate in the study, specifically a) currently taking the P450 enzyme inhibitors (erythromycin, ketoconazole, itraconazole, saquinavir), b) currently taking the protease inhibitor ritonavir, c) currently taking nitrates or have a history of requiring nitrates treatment, d) have left ventricular outflow obstruction (i.e., aortic stenosis, idiopathic hypertrophic subaortic stenosis as confirmed by review of standard of care echo received before admission to rehabilitation), e) have severely impaired autonomic control of blood pressure, f) have previous history of symptomatic hypotension, g) have severely impaired hepatic function, h) is pregnant or become pregnant during the course of the study, i) Any medical condition which, in the opinion of the investigator, may compromise compliance with the objectives and/or procedures of the protocol.
• scores > 50 on the upper extremity section of the Fugl-Meyer or no walking/gait impairment
• For the MRI portion of the study only:
• contraindication to MRI: ferrous metal in body, lead included body art, claustrophobia, pacemaker
• allergic to or had previous reaction to gadolinium

Where it is running

• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.